ANAB - Company ID 0001370053
The table below shows ANAPTYSBIO, INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.92M | -$10.70M | -$37.25M | -$24.57M | -$21.01M | -$23.20M |
| Capital expenditure | $17.00K | $35.00K | $27.00K | $175.00K | $55.00K | $317.00K |
| Investing cash flow | $34.98M | $14.85M | $68.62M | $85.40M | -$312.91M | $56.73M |
| Dividends paid | - | - | - | - |
ANAPTYSBIO, INC reported operating cash flow of $19.70M for fiscal year 2025. That is up 114.6% from -$135.34M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$9.03M (FY 2016) to $19.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | $0.00 | $4.42M | $0.00 | $37.53M | $0.00 | - |
| Financing cash flow | $1.21M | -$28.59M | -$13.63M | -$37.57M | $4.61M | $167.00K |